文献速递认知障碍与痴呆

50-95岁认知正常人群脑β-淀粉样变、tau蛋白病和神经变性的年龄与性别特异性患病率:一项横断面研究

Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
PubMed 文献 · Lancet Neurol · 2017-04-26

该研究基于梅奥诊所衰老研究队列,纳入435例完成淀粉样PET、tau PET和MRI的认知正常者及1113例完成淀粉样PET和MRI者,按ATN分类系统分组。结果显示ATN各组年龄分布不同,A+T+N+在约80岁后最常见,85岁时超过90%的男女至少有一项生物标志物异常。

要点

  • ATN生物标志物分类可识别认知正常人群中异质性病理特征。
  • A+T+N+和A-T+N+患病率随年龄增长而增加,A-T-N-则下降。
  • 约80岁后A+T+N+成为最常见分组,85岁时超90%男女至少一项异常。

核心结论

  • 纤维状tau沉积生物标志物可与β-淀粉样变和神经变性标志物联合,更全面刻画人群中的异质性病理特征。
  • 认知正常人群中可识别淀粉样蛋白依赖性和非依赖性病理特征。
  • 各ATN分组患病率随年龄显著变化,保持认知正常者向更多生物标志物异常进展。

研究设计与样本

  • 基于梅奥诊所衰老研究的横断面研究,采用医疗记录链接系统随机抽取50-89岁人群并按年龄和性别分层。
  • 联合分析435例完成淀粉样PET、tau PET和MRI者及1113例完成淀粉样PET和MRI但未完成tau PET者的数据。

主要发现

  • 各ATN分组人数:A-T-N- 165例,A-T+N- 35例,A-T-N+ 63例,A-T+N+ 19例,A+T-N- 44例,A+T+N- 25例,A+T-N+ 35例,A+T+N+ 49例。
  • 在65岁时86%、80岁时51%的临床前阿尔茨海默病2或3期(A+T+N-、A+T-N+、A+T+N+)个体中,tau PET与神经变性标志物不一致;在疑似非阿尔茨海默病病理生理(A-T+N-、A-T-N+、A-T+N+)个体中,65岁时92%、80岁时78%不一致。

临床怎么用

  • 在认知正常老年人中可依据ATN生物标志物谱评估病理进展风险。
  • 年龄增长与ATN异常项增多相关,80岁后A+T+N+最常见。
  • tau PET与神经变性标志物在多数临床前阿尔茨海默病或疑似非阿尔茨海默病病理生理个体中不一致,需综合解读。

局限性

  • 横断面设计无法推断因果关系或纵向变化。
  • 部分参与者未完成tau PET,采用多分类模型联合分析可能引入选择偏倚。
  • 研究人群来自特定社区(Olmsted County),外推性需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A new classification for biomarkers in Alzheimer's disease and cognitive ageing research is based on grouping the markers into three categories: amyloid deposition (A), tauopathy (T), and neurodegeneration or neuronal injury (N). Dichotomising these biomarkers as normal or abnormal results in eight possible profiles. We determined the clinical characteristics and prevalence of each ATN profile in cognitively unimpaired individuals aged 50 years and older. METHODS: All participants were in the Mayo Clinic Study of Aging, a population-based study that uses a medical records linkage system to enumerate all individuals aged 50-89 years in Olmsted County, MN, USA. Potential participants are randomly selected, stratified by age and sex, and invited to participate in cognitive assessments; individuals without medical contraindications are invited to participate in brain imaging studies. Participants who were judged clinically as having no cognitive impairment and underwent multimodality imaging between Oct 11, 2006, and Oct 5, 2016, were included in the current study. Participants were classified as having normal (A-) or abnormal (A+) amyloid using amyloid PET, normal (T-) or abnormal (T+) tau using tau PET, and normal (N-) or abnormal (N+) neurodegeneration or neuronal injury using cortical thickness assessed by MRI. We used the cutoff points of standard uptake value ratio (SUVR) 1·42 (centiloid 19) for amyloid PET, 1·23 SUVR for tau PET, and 2·67 mm for MRI cortical thickness. Age-specific and sex-specific prevalences of the eight groups were determined using multinomial models combining data from 435 individuals with amyloid PET, tau PET, and MRI assessments, and 1113 individuals who underwent amyloid PET and MRI, but not tau PET imaging. FINDINGS: The numbers of participants in each profile group were 165 A-T-N-, 35 A-T+N-, 63 A-T-N+, 19 A-T+N+, 44 A+T-N-, 25 A+T+N-, 35 A+T-N+, and 49 A+T+N+. Age differed by ATN group (p<0·0001), ranging from a median 58 years (IQR 55-64) in A-T-N- and 57 years (54-64) in A-T+N- to a median 80 years (75-84) in A+T-N+ and 79 years (73-87) in A+T+N+. The number of APOE ε4 carriers differed by ATN group (p=0·04), with carriers roughly twice as frequent in each A+ group versus the corresponding A- group. White matter hyperintensity volume (p<0·0001) and cognitive performance (p<0·0001) also differed by ATN group. Tau PET and neurodegeneration biomarkers were discordant in most individuals who would be categorised as stage 2 or 3 preclinical Alzheimer's disease (A+T+N-, A+T-N+, and A+T+N+; 86% at age 65 years and 51% at age 80 years) or with suspected non-Alzheimer's pathophysiology (A-T+N-, A-T-N+, and A-T+N+; 92% at age 65 years and 78% at age 80 years). From age 50 years, A-T-N- prevalence declined and A+T+N+ and A-T+N+ prevalence increased. In both men and women, A-T-N- was the most prevalent until age late 70s. After about age 80 years, A+T+N+ was most prevalent. By age 85 years, more than 90% of men and women had one or more biomarker abnormalities. INTERPRETATION: Biomarkers of fibrillar tau deposition can be included with those of β-amyloidosis and neurodegeneration or neuronal injury to more fully characterise the heterogeneous pathological profiles in the population. Both amyloid- dependent and amyloid-independent pathological profiles can be identified in the cognitively unimpaired population. The prevalence of each ATN group changed substantially with age, with progression towards more biomarker abnormalities among individuals who remained cognitively unimpaired. FUNDING: National Institute on Aging (part of the US National Institutes of Health), the Alexander Family Professorship of Alzheimer's Disease Research, the Mayo Clinic, and the GHR Foundation.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Jack CR, Wiste HJ, Weigand SD, et al. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. Lancet Neurol. 2017. PMID: 28456479. doi:10.1016/S1474-4422(17)30077-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。